ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
Nucresiran is ALNY's next-generation RNAi therapeutic, which is being developed leveraging the company's proprietary IKARIA platform. The ongoing phase I study evaluates the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic effects of nucresiran in 48 healthy adult subjects, who have been randomized in a ratio of 3:1 to receive either a single ascending dose of nucresiran or placebo. The study's primary endpoint is safety and secondary endpoints include the change from baseline in serum TTR over time, as well as characterization of plasma and urine PK of nucresiran. Per the data from an interim analysis of the phase I ATTR amyloidosis study, it was observed that a single 300 mg or higher dose of nucresiran quickly reduced serum TTR levels with low inter-patient variability, by more than 90% within 15 days, sustained through at least six months. At these dosage strengths, the reduction of mean TTR levels peaked at more than 96% by Day 29. Furthermore, serum TTR levels
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target lowered by analysts at Scotiabank from $310.00 to $300.00. They now have a "sector outperform" rating on the stock.MarketBeat
- Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Morgan Stanley from $275.00 to $284.00. They now have an "equal weight" rating on the stock.MarketBeat
- Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.MarketBeat
- Alnylam: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- https://seekingalpha.com/article/4758153-alnylam-waiting-for-regulatory-updates-in-march [Seeking Alpha]Seeking Alpha
ALNY
Earnings
- 2/13/25 - Beat
ALNY
Sec Filings
- 2/13/25 - Form SCHEDULE
- 2/13/25 - Form 10-K
- 2/13/25 - Form 8-K
- ALNY's page on the SEC website